Haley Gittleman Selected Research

belzutifan

11/2022

FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Haley Gittleman Research Topics

Disease

8	Neoplasms (Cancer) 10/2023 - 01/2016
4	Renal Cell Carcinoma (Grawitz Tumor) 03/2024 - 11/2022
4	Brain Neoplasms (Brain Tumor) 01/2020 - 10/2016
4	Glioblastoma (Glioblastoma Multiforme) 10/2019 - 08/2017
3	Nausea 02/2024 - 11/2022
2	Disease Progression 02/2024 - 01/2023
2	Fatigue 01/2023 - 11/2022
2	Anemia 01/2023 - 11/2022
2	Glioma (Gliomas) 05/2019 - 01/2018
2	HIV Infections (HIV Infection) 01/2019 - 01/2017
1	Breast Neoplasms (Breast Cancer) 02/2024
1	Vomiting 02/2024
1	Dyslipidemias (Dyslipidemia) 02/2024
1	Ovarian Neoplasms (Ovarian Cancer) 10/2023
1	Constipation 01/2023
1	Prostatic Neoplasms (Prostate Cancer) 01/2023
1	von Hippel-Lindau Disease (von Hippel Lindau Disease) 11/2022
1	Headache (Headaches) 11/2022
1	Hypoxia (Hypoxemia) 11/2022
1	Primitive Neuroectodermal Tumors (PNET) 11/2022
1	Hemangioblastoma 11/2022
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 11/2022
1	Dizziness (Lightheadedness) 11/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2019
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2019
1	Neurofibromatoses (Neurofibromatosis) 01/2018
1	Necrosis 08/2017
1	Neuroinflammatory Diseases 01/2017
1	Inflammation (Inflammations) 01/2017

Drug/Important Bio-Agent (IBA)

3	Biomarkers (Surrogate Marker)IBA 05/2019 - 01/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2024 - 01/2017
2	Tyrosine Kinase InhibitorsIBA 02/2024 - 10/2023
2	N-oxydiethylene-2-benzothiazole sulfenamide (MMBT)FDA Link 01/2020 - 05/2019
2	Complement System Proteins (Complement)IBA 05/2019 - 01/2016
2	Temozolomide (Temodar)FDA LinkGeneric 05/2019 - 09/2017
2	MethyltransferasesIBA 05/2019 - 09/2017
2	Mitochondrial DNA (mtDNA)IBA 01/2019 - 01/2017
1	Immune Checkpoint InhibitorsIBA 03/2024
1	ErbB Receptors (EGF Receptor)IBA 02/2024
1	elacestrantIBA 02/2024
1	Estrogen ReceptorsIBA 02/2024
1	Estrogen Receptor alphaIBA 02/2024
1	PlatinumIBA 10/2023
1	Folic Acid (Vitamin M)FDA LinkGeneric 10/2023
1	mirvetuximab soravtansineIBA 10/2023
1	Immunoconjugates (Immunoconjugate)IBA 10/2023
1	taxaneIBA 01/2023
1	Androgen Receptors (Androgen Receptor)IBA 01/2023
1	LutetiumIBA 01/2023
1	AntigensIBA 01/2023
1	177Lu-PSMA-617IBA 01/2023
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2023
1	Glucose (Dextrose)FDA LinkGeneric 11/2022
1	belzutifanIBA 11/2022
1	CreatinineIBA 11/2022
1	Indicators and Reagents (Reagents)IBA 05/2019
1	Class 2 Receptor-Like Protein Tyrosine PhosphatasesIBA 05/2019
1	Cell Adhesion MoleculesIBA 05/2019
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 05/2019
1	hydroxide ionIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 09/2017
1	HLA-DR Antigens (HLA-DR)IBA 08/2017
1	Interleukin-8 (Interleukin 8)IBA 01/2017
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	Transferrin (beta 2 Transferrin)IBA 01/2017
1	IronIBA 01/2017
1	Ceruloplasmin (Ferroxidase)IBA 01/2017

Therapy/Procedure

7	Therapeutics 03/2024 - 10/2016
2	Drug Therapy (Chemotherapy) 01/2023 - 10/2019
1	Nephrectomy 03/2024
1	Castration 01/2023
1	Hospital to Home Transition 01/2018
1	Radiotherapy 08/2017
1	Precision Medicine 10/2016
1	Lasers (Laser) 10/2016
1	Laser Therapy (Surgery, Laser) 10/2016